bedoradrine

12/01/2012 - "Study MN-221-CL-005 assessed the safety profile and preliminary efficacy of MN-221 in patients with stable moderate-to-severe asthma when given as a fixed dose over 1- or 2- hr infusion. "
12/01/2012 - "Trial MN-221-CL-004 assessed the safety profile and preliminary efficacy of MN-221 in escalating doses in patients with stable mild-to-moderate asthma. "
08/01/2014 - "The intravenous use of bedoradrine has demonstrated promising preliminary efficacy in existing clinical trials for exacerbated asthma. "
10/01/2015 - "The goal of this study was to evaluate the safety and efficacy of intravenous bedoradrine (MN-221), a highly selective β2-adrenergic agonist, as adjunct to standard therapy in the management of patients with acute exacerbation of asthma who did not respond to standard therapy. "
12/01/2012 - "Evaluation of bedoradrine sulfate (MN-221), a novel, highly selective beta2-adrenergic receptor agonist for the treatment of asthma via intravenous infusion."

08/01/2014 - "However, the efficacy of bedoradrine is still uncertain in exacerbated COPD. "
08/01/2014 - "This drug evaluation paper reviews the potential therapeutic agent bedoradrine, an ultraselective β2 agonist, which is currently under development for treating exacerbated asthma and COPD. "
08/01/2014 - "Bedoradrine for treating asthma and chronic obstructive pulmonary disease."

10/01/2015 - "The dyspnea scores were significantly improved for patients treated with bedoradrine compared to placebo (AUC0-2 hP < 0.005, AUC0-3 hP < 0.05). "
10/01/2015 - "Intravenous bedoradrine, in addition to standard therapy, did not significantly increase %FEV1 at 3 h, but it was associated with significantly improved dyspnea scores. "

06/01/2009 - "Bedoradrine is a promising drug for the treatment of preterm labor in obstetrical practice because it has better selectivity for beta(2)-AR and specificity for the uterus than currently used agents and may effectively delay spontaneous delivery."
02/01/2006 - "KUR-1246 is a promising drug for the treatment of preterm labor in obstetric practice because it is as efficacious as currently used agents yet less likely to produce direct effects on the fetus."